ViaDerma Provides an Update on Current & Future Business Activities
ViaDerma Provides an Update on Current & Future Business Activities
The Company has expanded its current wound care licensing agreement to 11 states and expects to be nationwide within the next 12 months
該公司已將目前的傷口護理許可協議擴展到 11 個州，並預計在未來 12 個月內將在全國范圍內進行
LOS ANGELES, March 02, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to provide an update on current business activities.
洛杉磯，2023 年 3 月 2 日（環球美通社）-維亞德瑪有限公司（OTC 粉紅色交易代碼：VDRM）很高興提供有關當前業務活動的最新信息。
- ViaDerma has expanded its licensing agreement with a large wound care network. The licensee recently increased the number of states in which they operate to eleven. Per the agreement, ViaDerma receives $5,000 per month for each state in which the licensee is doing business. The addition of the new states increases ViaDerma's current royalties to $55,000 per month from this agreement. The wound care network has indicated their intent to add new states at a more rapid pace and believes they can be nationwide within the next twelve months.
- The Company has recently launched a new corporate website which is now ViaDerma.com. Redesigning the website was an important step in the company's ongoing efforts to develop and grow the brand by increasing name recognition, customer engagement, and new business worldwide.
- ViaDerma is currently in the process of seeking approval for insurance coverage benefits for Vitastem and Vitastem Ultra. Many insurance companies including Medicare and Medicaid offer over-the-counter benefits (OTC) for non-prescription or OTC products such as the products offered by ViaDerma.
- ViaDerMA 已經擴大了其許可協議與一個大型傷口護理網絡。持牌人最近將他們經營的州數量增加到 11 個。根據該協議，ViaDerMA 每月為被授權人開展業務的每個州收取 $5,000 美元。新州的增加將 ViaDerMA 目前的特許權使用費從本協議中提高到每月 55,000 美元。傷口護理網絡已表明他們打算以更快的速度增加新州，並相信它們可以在未來十二個月內遍布全國范圍內。
- 該公司最近推出了一個新的企業網站，該網站現已成為 Viaderma.com。重新設計網站是該公司不斷努力通過增加名稱認可度，客戶參與度和全球新業務來發展和發展品牌的重要一步。
- ViaDerma 目前正在尋求批准為維塔斯特姆和維塔斯特姆超保險承保福利的過程。包括醫療保險和醫療補助在內的許多保險公司都為非處方或非處方產品（OTC）提供非處方或非處方產品（OTC），例如 ViaDerMA 提供的產品。
President & CEO, Dr. Chris Otiko said, "We are off to a great start in this new year after enduring some delays because of pandemic related supply chain issues and our strict internal quality control measures. We are happy to be back on track and very excited for what the future holds."
總裁兼首席執行官 Chris Otiko 博士表示：「由於與大流行相關的供應鏈問題以及我們嚴格的內部質量控制措施而忍受了一些延誤，我們在新的一年開始很好。我們很高興能回到正軌上，並為未來的發展感到非常興奮。」
"Our current marketing efforts are geared towards targeting institutions, hospitals, and doctor's offices domestically and internationally for product sales, along with licensing the use of Vitastem and Vitastem Ultra. So far, we have received overwhelmingly positive feedback from those who have tested our products and expect this to result in larger volume sales in 2023."
「我們目前的行銷工作是針對國內和國際的機構、醫院和醫生辦公室進行產品銷售，同時授權使用 Vitastem 和 Vitastem Ultra。到目前為止，我們已經收到了來自那些測試過我們產品並預計這將在 2023 年帶來更大的銷售量的用戶的絕大積極反饋。」
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit:
關於維亞德瑪公司
ViaDerma, Inc.（OTC：VDRM）是一家上市的專業製藥公司，致力於將新產品推向市場，並將其創新技術授權給製藥行業在各種治療領域的當前領導者。如需詳細資訊，請造訪：
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management's beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
任何對未來表現的預測都是證券法下的「前瞻性聲明」。這些聲明包括在內，讓潛在投資者有機會了解管理層對未來的信念和意見，以便他們可以將這些信念和意見作為評估投資的眾多因素中的一個因素。
Contact information:
聯絡資訊：
Investor Relations
投資者關係
Email: info@viadermalicensing.com
電郵地址:info@viadermalicensing.com
Phone: 310-734-6111
電話：
Follow ViaDerma on Twitter:
在推特上關注維亞德瑪：
Follow ViaDerma on Facebook:
在臉書上關注維亞德瑪：